贝兰他单抗莫福汀联合蛋白酶体抑制方案对比早期复发骨髓瘤对照方案的疗效:系统综述与网络Meta分析
本研究通过系统文献综述(2021年12月至2024年2月4日)和网络Meta分析,间接比较贝兰他单抗莫福汀联合硼替佐米和地塞米松(BVd)与12种对照方案在复发/难治多发性骨髓瘤(RRMM)中的疗效。BVd在无进展生存期和总生存期方面均优于所有对照方案,包括达雷妥尤单抗联合卡非佐米和地塞米松、伊沙妥昔单抗联合卡非佐米和地塞米松以及达雷妥尤单抗联合硼替佐米和地塞米松。
要点
- BVd对比所有12种对照方案均改善无进展生存期。
- BVd对比其他方案亦改善总生存期。
- 纳入研究均含蛋白酶体抑制剂(硼替佐米或卡非佐米)加地塞米松。
核心结论
- 贝兰他单抗莫福汀联合硼替佐米和地塞米松在RRMM早期治疗线中较对照方案改善无进展生存期和总生存期。
研究设计与样本
- 系统文献综述(2021年12月至2024年2月4日)筛选出12项对照研究(共12种对照方案),均与DREAMM-7研究相连并纳入网络Meta分析。
- 主要分析为各研究意向治疗人群的无进展生存期,次要分析评估其他终点,并按来那度胺暴露、难治性等特征进行亚组分析。
主要发现
- BVd对比所有对照方案均改善无进展生存期,包括达雷妥尤单抗联合卡非佐米和地塞米松、伊沙妥昔单抗联合卡非佐米和地塞米松以及DVd。
- 贝兰他单抗莫福汀联合硼替佐米和地塞米松对比其他方案亦改善总生存期。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the Phase 3 DREAMM-7 study of patients with relapsed/refractory multiple myeloma (RRMM) who received ≥ 1 prior therapy, belantamab mafodotin plus bortezomib and dexamethasone (BVd) demonstrated a progression-free survival (PFS) benefit versus daratumumab plus bortezomib and dexamethasone (DVd). This study aimed to indirectly compare the efficacy of BVd against alternative regimens in this patient population. A systematic literature review (SLR; December 2021-February 4, 2024) was performed to identify relevant efficacy data. Studies were selected based on the Population-Intervention-Comparators-Outcomes-Study design framework criteria and independently reviewed for inclusion in the network meta-analysis (NMA) if they had a connection to DREAMM-7 (approved in the US or EU, or likely to be a future DREAMM-7 comparator). Each trial had a common comparator arm, allowing for a connected network between the trials and linkage by shared treatments. The primary analysis was PFS in the intent-to-treat population from each study, and secondary analyses examined other endpoints. All endpoints were also evaluated in subgroups by lenalidomide-exposure, -refractoriness, and other patient characteristics. The SLR identified 12 comparator studies comprising 12 comparator regimens (each contained a proteasome inhibitor [bortezomib or carfilzomib] plus dexamethasone), all of which were included in the NMA with the DREAMM-7 study. BVd improved PFS versus all comparators, including daratumumab plus carfilzomib and dexamethasone, isatuximab plus carfilzomib and dexamethasone, and DVd. Overall survival was also improved by belantamab mafodotin plus bortezomib and dexamethasone over the other regimens. This study provides compelling evidence for belantamab mafodotin, plus bortezomib and dexamethasone, in early lines of treatment for RRMM.
引用
- Richter J, Nooka A, Rodríguez-Otero P, et al. Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta-Analysis. Am J Hematol. 2025. PMID: 40143674. doi:10.1002/ajh.27661
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。